Welcome, Guest. Please login or register.
November 23, 2017, 06:49:08 AM

Login with username, password and session length

  • Total Posts: 722679
  • Total Topics: 58734
  • Online Today: 333
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: New Combination Of Antibody And Bacterial Toxins To Kill Latent HIV  (Read 2102 times)

0 Members and 1 Guest are viewing this topic.

Offline Tadeys

  • Member
  • Posts: 162
It’s been years since antiretroviral therapy has allowed HIV patients to live long, healthy, and happy lives. But it’s also been a long time since scientists have tried to find a cure for HIV, with latent HIV cells hiding in the body posing the biggest obstacle.

Researchers have come up with plenty of approaches to eradicate these difficult-to-reach, latent HIV hideouts – combination therapies, vaccines, zinc finger nuclease therapy.

In the midst of all these possibilities and yet no cure, another research project has been published. A new study out of the University of North Carolina School of Medicine found a new way to destroy these hidden HIV-infected cells. The researchers tested mice that had human cells comprising their immune systems, known as BLT mice, and found that a combination of both a bacterial toxin and an antibody could enter HIV-infected cells and eliminate them.  This joint antibody-toxin approach would be more effective in killing latent HIV viruses than antiretroviral therapy.

“Our work provides evidence that HIV-infected cells can be tracked down and destroyed throughout the body,” Dr. Victor Garcia, professor of medicine and senior author of the study, said in a press release.

Though antiretroviral therapy (ART) is extremely effective in pushing HIV levels down to a diminished low, small amounts of latent, or hidden, HIV viruses remain in the system. Though ART cannot destroy these latent viruses, Garcia believes the combination of the bacterial toxin and antibody could.

The combination compound was developed by co-authors Dr. Edward Berger and Dr. Ira Pastan, from the National Institutes of Allergy and Infectious Diseases. The antibody is called 3B3 and is combined with a bacterial toxin known as PE38; the authors believed that the antibody would be able to identify a certain HIV protein in cells. The antibody would then attach to the protein, allowing the bacterial toxin to enter the HIV cell and destroy it. According to the press release, Garcia and his team found that “the molecular missile [compound] had killed the vast majority of persistent HIV-infected cells that had been actively producing the virus despite traditional therapy.” This allowed for a large drop in the amount of HIV-infected cells in the body – six times lower than before.

“The [mice with human immune system] model represents a platform in which virtually any novel approach to HIV eradication can be tested,” Garcia said, according to the press release. “It helps us prioritize which therapeutic approaches should be advanced to clinical implementation in humans. This study shows that it’s possible to attack and kill hidden HIV-infected cells that standard therapy can’t touch.”


Offline GoForIt

  • Member
  • Posts: 206
Re: New Combination Of Antibody And Bacterial Toxins To Kill Latent HIV
« Reply #1 on: January 10, 2014, 03:53:22 PM »
Sounds like a step in the right direction.
08/09/2013  Diagnosed WB positive
08/20/2013  CD4-506(28%)  VL-10,800
09/12/2013  CD4-391(28%)  VL-14,900
09/17/2013  Start ART (Truvada + Tivicay)
10/11/2013  CD4-377(26%)  VL-UD
12/20/2013  CD4-590(??%)  VL-UD
03/18/2014  CD4-660(29%)  VL-UD
07/22/2014  CD4-613(29%)  VL-UD
08/01/2014   Start Phase 3 TAF (Truvada 2.0) Clinical Trial (TAF + Tivicay)
10/09/2014  CD4-498(29.5%) VL-UD
11/06/2014  CD4-600(30.2%) VL-UD
01/30/2015  CD4-529(31.3%) VL-UD
07/25/2015  CD4-742(36.5%) VL-UD
10/06/2015  CD4-765(28.9%) VL-UD
01/05/2016  CD4-907(33.1%) VL-UD
03/24/2016  CD4-770(33.5%) VL-UD
06/20/2016  CD4-850(35.4%) VL-UD

Dr. Mark Wainberg on Dolutegravir:
Video 1: https://youtu.be/wCXOgLJqJAY
Video 2: https://youtu.be/DKiaD7fHO-s
Antiretroviral Therapy in 2016: http://tinyurl.com/zk45x6e

Offline geobee

  • Member
  • Posts: 351
Re: New Combination Of Antibody And Bacterial Toxins To Kill Latent HIV
« Reply #2 on: January 10, 2014, 05:43:28 PM »
This is very similar to the radio-immunotherapy approach which has an antibody attached to a 4-hour radioactive particle.  This seems a little less scary.

I can't get over the mind shift in the last 5 years since I've been infected.  Science is making real progress against these latent reservoirs.  Really cool.

PS -- make the switch from Reyataz/Truvada/Norvir to Stribild.  Easy, one pill, one co-pay.  No irritating mistakes at the pharmacy.  No yellow skin/eyes.  Less diarrhea.  And, I know this sounds a little nutty, but I feel less depressed/happier.  Life is good.

Offline Skydrake

  • Member
  • Posts: 82
« Last Edit: January 11, 2014, 02:07:26 PM by Skydrake »

Offline Dr.Strangelove

  • Member
  • Posts: 215
Re: New Combination Of Antibody And Bacterial Toxins To Kill Latent HIV
« Reply #4 on: January 12, 2014, 02:23:15 PM »
Here's a link to the paper.

Antiretroviral therapy (ART) improves the quality of life for HIV infected individuals. However, ART is currently a lifelong commitment because HIV persists during treatment despite being suppressed below detection. If therapy is stopped, the HIV reappears. A concerted effort is ongoing to develop new eradication therapies to prevent virus rebound, but there are challenges to be overcome. Our work is a major step forward in this process. We measured persistent HIV throughout the body during ART using bone marrow/liver/thymus (BLT) humanized mice, a model validated to study HIV persistence. HIV infected BLT mice were treated with tenofovir, emtricitabine and raltegravir. Despite documented tissue penetration by these drugs, we found that HIV expression persists in cells isolated from all the tissues analyzed (bone marrow, thymus, spleen, lymph nodes, liver, lung, intestines and peripheral blood cells). We therefore complemented ART with an immunotoxin that specifically kills HIV expressing cells while leaving other cells untouched. Our results demonstrate a dramatic reduction in persistent HIV throughout the body resulting from the killing of virus producing cells. Thus, our study provides new insights into the locations of HIV persistence during ART and a demonstration that persistent HIV can be successfully targeted inside the body.


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.